|Articles|May 1, 1998

May 1998
Volume 4
Issue 5

Prevention of Nonsteroidal Anti-Inflammatory Drug-Induced Gastropathy: Clinical and Economic Implications of a Single-Tablet Formulation of Diclofenac/Misoprostol

Author(s)Jay L. Goldstein, MD, Leanne R. Larson, MHA, Beverly D. Yamashita, RN

Download PDF: Prevention of Nonsteroidal Anti-Inflammatory Drug-Induced Gastropathy: Clinical and Economic Implications of a Single-Tablet Formulation of Diclofenac/Misoprostol

Articles in this issue

about 28 years ago

Article

Experience with a Managed Care Approach to HIV Infection: Effectiveness of an Interdisciplinary Team

about 28 years ago

Article

Regulating the Financial Incentives Facing Physicians in Managed Care Plans

about 28 years ago

Article

Evaluation of "Solitary" Thyroid Nodules in a Community Practice: A Managed Care Approach

about 28 years ago

Article

Patient Waiting Times in a Physician's Office

about 28 years ago

Article

Infertility Services and Managed Care

about 28 years ago

Article

The development and Implementation of Normal Vaginal Delivery Clinical Pathways in a Large Multihospital Health System

about 28 years ago

Article

Nonhormonal Alternatives to Treating Menopausal Symptoms

about 28 years ago

Article

Patient Satisfaction and Quality of Life: Humanistic Outcomes

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

ByVivian T. E. Tar, PharmD, MBA

July 8th 2026

Prevention of Nonsteroidal Anti-Inflammatory Drug-Induced Gastropathy: Clinical and Economic Implications of a Single-Tablet Formulation of Diclofenac/Misoprostol

Articles in this issue

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Trending on AJMC

FAQs: FDA Lawsuit Challenges E-Cigarette Enforcement Policy, PMTA Guidance

Medicaid MFN Pricing Could Save $8.6 Billion

Active US Drug Shortages Rise for Third Straight Quarter

Cognitive Rehabilitation Improves Functional Outcomes in Long COVID Brain Fog

Adding Epcoritamab to R2 in R/R Follicular Lymphoma Meets Cost-Effectiveness Tests